Talazoparib plus enzalutamide improved PSA response versus enzalutamide alone in a phase 2 trial

Nature Medicine reports that, in a randomized phase 2 trial, patients with metastatic hormone-sensitive prostate cancer had an improved PSA response with talazoparib plus enzalutamide compared with enzalutamide alone. Talazoparib is a PARP inhibitor; enzalutamide is an androgen receptor inhibitor.